Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

@article{Gelfand2015CeftolozaneTazobactamTO,
  title={Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.},
  author={Michael S. Gelfand and Kerry O. Cleveland},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2015},
  volume={61 5},
  pages={
          853-5
        }
}
  • M. Gelfand, K. Cleveland
  • Published 1 September 2015
  • Biology
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
View on PubMed
academic.oup.com
47 Citations
Highly Influential Citations
2
Background Citations
10
Methods Citations
1
Results Citations
2

Tables from this paper

47 Citations

Citation Type

Citation Type

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
TLDR
The studies identified in this review demonstrate that C/T shows similar outcomes as those seen in clinical trials, despite the higher frequency of multidrug-resistant pathogens, and comorbidities that may have been excluded from the trials.
Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence
TLDR
C/T may be a valid therapeutic option to treat multidrug-resistant (MDR), extensively drug- resistant (XDR), pandrug- resisting (PDR), and carbapenem-resistant(CR) PA infections, however, further data are necessary to define the optimal treatment dosage and duration.
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients
TLDR
The implementation of algorithms focused on prompt revision of antibiotic regimens guided by results of conventional and rapid diagnostic methodologies, appropriate place in therapy of novel beta-lactams, implementation of strategies for sparing the broadest-spectrum antibiotics, and pharmacokinetic/pharmacodynamic optimization of antibiotic dosing regimens is strongly suggested.
Ceftolozane/Tazobactam-Induced Leukocytosis and Clinical Failure in a Patient Being Treated for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Pseudomonas aeruginosa: a Case Report
TLDR
This case report delineates the first published case of ceftolozane/tazobactam-induced leukocytosis and clinical failure when utilized in a high-dose regimen for a patient being treated for ventilator-associated pneumonia secondary to carbapenem-resistant P. aeruginosa.
Hospital-Acquired and Ventilator-Associated Pneumonia
Multidrug resistant bacteremia in hematopoietic stem cell transplant recipients.
TLDR
Low prevalence of MDR bacteremia in HSCT recipients but high attributable mortality rate, requiring reinforcement of hygiene measures is investigated.
Real-world use of ceftolozane/tazobactam: a systematic literature review
TLDR
In comparative studies, C/T was as effective as aminoglycoside- or polymyxin-based regimens, and in some instances, significantly more effective.
Systematic Literature Review of Real-World Evidence of C Eftolozane/Tazobactam for the Treatment of Respiratory Infections
TLDR
The studies identified in this review demonstrate that C/T shows similar outcomes as those seen in clinical trials, despite the higher frequency of multidrug-resistant pathogens, and comorbidities/conditions that may have been excluded from the trials.
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia
TLDR
Ceftolozane-tazobactam is a combination of a novel semi-synthetic fifth-generation cephalosporin with a well-established beta-lactamase inhibitor that enables the molecule to overcome the most common anti-drug resistant mechanisms of bacteria.
Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
We evaluated β-lactam-resistant baseline Enterobacterales species and Pseudomonas aeruginosa lower respiratory tract isolates collected during the ASPECT-NP phase 3 clinical trial evaluating the…
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 10 REFERENCES
Clinical Infectious Diseases
TLDR
It is a mystery as to why Saudi Arabia is the epicenter of MERS compared to other Middle Eastern countries or why it has not occurred in African countries, and there is also no solid information in 35% of cases that occurred in Saudi Arabia in the year as described above.
Bloodstream infection caused by extended spectrum β - lactamase - producing gram - negative bacteria : how to defi ne the best treatment regimen ?
  • Clin Infect Dis
  • 2015
Bloodstream infection caused by extended spectrum β-lactamaseproducing gram-negative bacteria: how to define the best treatment regimen?
  • Clin Infect Dis
  • 2015
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
TLDR
This phase 3 trial compared ceftolozane/tazobactam plus metronidazole vs meropenem for the treatment of complicated intra-abdominal infections with high rates of presumed microbiological eradication of Enterobacteriaceae and Pseudomonas aeruginosa.
Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?
  • F. Pérez, R. Bonomo
  • Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
emergence of CTX-M–type enzymes [3].Presently, in E. coli the CTX-M β-lactamases far outnumber the TEM and SHV types, and are linked with the dissemination of the “high-risk clone” sequence type (ST)…
Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP) Available at: https://clinicaltrials.gov/ct2/show/ NCT02070757
  • Accessed
  • 2015
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*
TLDR
The findings suggest that ventilator-associated pneumonia remains a common ICU infection and that P. aeruginosa is one of the most common causative pathogens.
DOI: 10.1093/cid/civ411 CORRESPONDENCE @BULLET CID
  • DOI: 10.1093/cid/civ411 CORRESPONDENCE @BULLET CID
The Author 2015 Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. permissions@oup.com
  • The Author 2015 Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. permissions@oup.com